TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12540205

Group type: EXPERIMENTAL
Intervention: Length-normalized pulse photoplethysmography (D/l)
Number of subjects: 25
Study: 9681402

Group type: EXPERIMENTAL
Intervention: 0.4 g/kg HBOC‐201
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hydroxyethyl starch (mw 70,000)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups (HBOC‐201 and hydroxyethyl starch)
Number of subjects: 12
Study: 7988131

Group type: EXPERIMENTAL
Intervention: Sucralfate (2 g every 8 hrs)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (20 mL of sterile water every 8 hrs)
Number of subjects: 26
Study: 2521989

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (500 micrograms)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (lower doses)
Number of subjects: 13
Study: 4567765

Group type: EXPERIMENTAL
Intervention: Marijuana (dosage and smoking procedure standardized)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo (dosage and smoking procedure standardized)
Number of subjects: 81
Study: 30169915

Group type: EXPERIMENTAL
Intervention: OIT with pasteurized egg white (PEW), target dose 3.3 g PEW proteins, buildup pattern PI (30% weekly plus 5% daily increments)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: OIT with pasteurized egg white (PEW), target dose 3.3 g PEW proteins, buildup pattern PII (30% weekly increments)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (egg-free diet)
Number of subjects: 101
Study: 29619533

Group type: EXPERIMENTAL
Intervention: CBD (600 mg/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 26706022

Group type: EXPERIMENTAL
Intervention: Probiotic supplements (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 40
Study: 24063317

Group type: EXPERIMENTAL
Intervention: 12 individual life review sessions and co‐creating a life story book (LSB)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Personal LSB created by their relatives as a 'gift'
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both pathways of creating LSBs
Number of subjects: 23
Study: 21094258

Group type: EXPERIMENTAL
Intervention: Anodal 2.0 mA tDCS for 30 min over right inferior frontal and right parietal cortex
Number of subjects: 96

Group type: COMPARATOR
Intervention: 0.1 mA tDCS
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Anodal 2.0 mA tDCS
Number of subjects: 96
Study: 20432043

Group type: EXPERIMENTAL
Intervention: Ultrasound turbinate reduction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Radiofrequency coblation technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Monopolar diathermy (electrocautery)
Number of subjects: 60
Study: 17509869

Group type: EXPERIMENTAL
Intervention: Epidural analgesia (group EA) with a 7‐mL epidural bolus 0.1% bupivacaine containing fentanyl 50 mug (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Combined spinal‐epidural analgesia (group CSEA) with intrathecal fentanyl 20 mug (n=20)
Number of subjects: 40
Study: 16450805

Group type: EXPERIMENTAL
Intervention: Early surgical evacuation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimal access surgical techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stereotactic aspirations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early and thorough clot evacuation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Techniques or adjuvant medical treatment to reduce clot expansion and rebleeding
Number of subjects: 0
Study: 12523676

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 6321

Group type: COMPARATOR
Intervention: Co-amilozide
Number of subjects: 6321
Study: 9700469

Group type: EXPERIMENTAL
Intervention: Triglyceride emulsion infusion (Lipid infusion study)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline infusion (Saline infusion study)
Number of subjects: 9
Study: 7623616

Group type: EXPERIMENTAL
Intervention: CI-979 (0.5-mg q6h, 1-mg q12h, 1-mg q6h, 2-mg q12h, 2-mg q6h, 2.5-mg q6h, and 3-mg q6h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2569324

Group type: EXPERIMENTAL
Intervention: Conventional (C) propranolol 160 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Long acting (LA) propranolol 160 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exercise testing
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propranolol pharmacology
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Propranolol concentration
Number of subjects: 24
Study: 913256

Group type: EXPERIMENTAL
Intervention: Alorbat
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Begrivac S
Number of subjects: 893
Study: 7176839

Group type: EXPERIMENTAL
Intervention: Prednisone treatment in patients with CAH (total group)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Prednisone treatment in patients with cirrhosis and CAH (Group I A)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Prednisone treatment in patients with probably cirrhosis and CAH (Group I B)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Prednisone treatment in patients compatible with but not diagnostic for cirrhosis and CAH (Group I C)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Prednisone treatment in patients without CAH (Group II A + B + C)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Control patients with CAH in all three subgroups
Number of subjects: 477
Study: 31543318

Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty (THR)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Hemiarthroplasty
Number of subjects: 105
Study: 28323796

Group type: EXPERIMENTAL
Intervention: Modern ring external fixation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Internal fixation
Number of subjects: 0
Study: 27446999

Group type: EXPERIMENTAL
Intervention: Calaject system (controlled flow technique)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Traditional syringe (control side)
Number of subjects: 25
Study: 24099893

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablets (FBTs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22676248

Group type: EXPERIMENTAL
Intervention: Ultrapro mesh
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prolene mesh
Number of subjects: 0
Study: 19322503

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (RTx)
Number of subjects: 351

Group type: COMPARATOR
Intervention: No external beam radiotherapy (non-RTx)
Number of subjects: 351
Study: 17308893

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily with oral etoposide starting at 50 mg every other day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oral etoposide alone (baseline pharmacokinetic studies)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily with oral etoposide
Number of subjects: 32
Study: 12877651

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with arachidonic acid (AA) at a dosage of 4 g/day for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oleic acid (OA) supplementation
Number of subjects: 0
Study: 11161542

Group type: EXPERIMENTAL
Intervention: GLY-GLN (500 ml glycyl-glutamine; 35 g GLN; 0.5 g/kg BW)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (1500 ml Vamin)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ALA-GLN (500 ml alanyl-glutamine; 35 g GLN; 0.5 g/kg BW)
Number of subjects: 30
Study: 9587049

Group type: EXPERIMENTAL
Intervention: Clovir (400 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Zovirax (400 mg)
Number of subjects: 24
Study: 7934013

Group type: EXPERIMENTAL
Intervention: Meso-ectomorphs (n = 65)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Mesomorphs (n = 50)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ectomorphs (n = 25)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ectomesomorphs (n = 40)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Overall injuries recorded
Number of subjects: 180
Study: 3192889

Group type: EXPERIMENTAL
Intervention: Geriatric consultation
Number of subjects: 451
Study: 4629183

Group type: EXPERIMENTAL
Intervention: D.S.C.G.-isoprenaline
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: D.S.C.G.
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Isoprenaline
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: D.S.C.G.-isoprenaline and D.S.C.G.
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Full dosage
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Reducing regimen
Number of subjects: 74
Study: 31821109

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy plus trastuzumab (CRxT)
Number of subjects: 3270

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy alone (CRx)
Number of subjects: 3270
Study: 31169661

Group type: EXPERIMENTAL
Intervention: Children with SAM
Number of subjects: 430

Group type: COMPARATOR
Intervention: Community controls
Number of subjects: 430
Study: 28017167

Group type: COMPARATOR
Intervention: PEEP 5 group
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PEEP 10 group
Number of subjects: 43
Study: 25807902

Group type: EXPERIMENTAL
Intervention: Full-mouth therapy (complete scaling and root planing in one stage within 24 h)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional therapy (scaling and root planing performed by quadrant over a period of 4 weeks)
Number of subjects: 180
Study: 23927056

Group type: EXPERIMENTAL
Intervention: Vertebral Body Stenting (VBS) system
Number of subjects: 100
Study: 21324193

Group type: EXPERIMENTAL
Intervention: Calcium acetate
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 19697106

Group type: EXPERIMENTAL
Intervention: Microemulsion system (ME3) containing 50% water
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral dosage form of tolterodine tartrate
Number of subjects: 0
Study: 17112848

Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 152
Study: 14760340

Group type: EXPERIMENTAL
Intervention: Urapidil (200 microg/kg intravenously, followed by 30 mg/d orally)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 10547171

Group type: EXPERIMENTAL
Intervention: Enhanced Compliance Program (ECP)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study: 8678058

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg once daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 1997054

Group type: EXPERIMENTAL
Intervention: Temazepam 30 mg in elixir formulation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Temazepam 30 mg in capsule formulation
Number of subjects: 100
Study: 6519348

Group type: EXPERIMENTAL
Intervention: Nimesulide 200 mg b.i.d.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Benzydamine
Number of subjects: 50
Study: 29752593

Group type: EXPERIMENTAL
Intervention: Kallidinogenase (150 units administered daily for 52 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: No kallidinogenase (control group)
Number of subjects: 39
Study: 30586261

Group type: EXPERIMENTAL
Intervention: HP/TAZ lotion
Number of subjects: 212

Group type: COMPARATOR
Intervention: TAZ
Number of subjects: 212

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 212

Group type: COMPARATOR
Intervention: HP
Number of subjects: 212
Study: 27780256

Group type: EXPERIMENTAL
Intervention: Smartphone application (APP) based on Android system to read 2D chemical barcodes
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: QR codes as an effective information carrier
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Linear interpolation angle cosine similarity algorithm (LIACSA)
Number of subjects: 3
Study: 24082027

Group type: EXPERIMENTAL
Intervention: Theory-based podcast intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control podcast
Number of subjects: 66
Study: 22353433

Group type: EXPERIMENTAL
Intervention: Web-based intervention (MyHealth Online, a patient portal with interactive health applications)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (health education website with various topics)
Number of subjects: 201
Study: 20823433

Group type: EXPERIMENTAL
Intervention: Fluorouracil plus folinic acid (20 mg/m² intravenous bolus injection followed by 425 mg/m² intravenous bolus injection given 1-5 days every 28 days)
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m² intravenous infusion once a week for 3 of every 4 weeks)
Number of subjects: 1088
Study: 18166759

Group type: EXPERIMENTAL
Intervention: Epinephrine ampules labeled with mass concentration (1 mg in 1 mL)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Epinephrine ampules labeled with ratio (1 mL of a 1:1000 solution)
Number of subjects: 28
Study: 16170757

Group type: EXPERIMENTAL
Intervention: Usual support measures and scripted serial telephone calls (16 calls during 96 weeks)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Usual support measures
Number of subjects: 282
Study: 12753315

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 273

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 273

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 273
Study: 11154807

Group type: EXPERIMENTAL
Intervention: Single-day praziquantel therapy (n=14)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Non-treatment (n=12)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Praziquantel treatment after non-treatment
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Seropositive patients (n=14)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Seronegative patients (n=12)
Number of subjects: 26
Study: 9055539

Group type: EXPERIMENTAL
Intervention: ECCE (Extracapsular Cataract Extraction)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PEA (Phacoemulsification and Aspiration)
Number of subjects: 39
Study: 1829091

Group type: EXPERIMENTAL
Intervention: Combination of long and short acting GnRH analogues (group II)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Induction of ovulation with decapeptyl/PFSH/HMG/HCG (group I)
Number of subjects: 34
Study: 6673029

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1,200 mg/day for 30 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 20
Study: 31907774

Group type: EXPERIMENTAL
Intervention: Home-Based Physical Activity Program (HB-PAP)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control
Number of subjects: 17
Study: 31237645

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor monotherapy after 3 months of DAPT (n=1495)
Number of subjects: 2993

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT) for 12 months (n=1498)
Number of subjects: 2993

Group type: EXPERIMENTAL
Intervention: P2Y12 inhibitor monotherapy
Number of subjects: 2993

Group type: COMPARATOR
Intervention: DAPT
Number of subjects: 2993
Study: 27667369

Group type: EXPERIMENTAL
Intervention: NAVIGATE treatment (comprehensive, team-based treatment program with ≥5h of SEE services per week)
Number of subjects: 404
Study: 27768193

Group type: EXPERIMENTAL
Intervention: Multimedia educational intervention consisting of interactive video tutorials (RLOs) delivered through DVD for TV or PC, and online.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RLOs watched fewer times by users with higher Internet competency.
Number of subjects: 0
Study: 25097397

Group type: EXPERIMENTAL
Intervention: Topical application of beta urogastrone (recombinant human epidermal growth factor) gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Betadine dressing (Control)
Number of subjects: 50
Study: 23210239

Group type: EXPERIMENTAL
Intervention: Rebamipide tablets from Yuanlijian (test)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rebamipide tablets from Otsuka (reference)
Number of subjects: 20
Study: 20703499

Group type: EXPERIMENTAL
Intervention: Trail running competition
Number of subjects: 23
Study: 18563785

Group type: EXPERIMENTAL
Intervention: Faecal occult blood test (FOBT) screening, rehydrated Hemoccult‐II, screened two to three times, compliance 70.0% (23,916 individuals)
Number of subjects: 68308

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 68308
Study: 15868146

Group type: EXPERIMENTAL
Intervention: Trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly for up to 840 days)
Number of subjects: 476
Study: 11840227

Group type: EXPERIMENTAL
Intervention: Selective serotonin re-uptake inhibitor (SSRI) treatment
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 10599031

Group type: EXPERIMENTAL
Intervention: Factor VIIa
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: von Willebrand factor (vWF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Group II (NIDDM)
Number of subjects: 16
Study: 8443642

Group type: EXPERIMENTAL
Intervention: In situ grafts
Number of subjects: 162

Group type: COMPARATOR
Intervention: Reversed vein grafts
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: In situ grafts (small veins subgroup)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Reversed vein grafts (small veins subgroup)
Number of subjects: 162
Study: 3094350

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (200 micrograms)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Reactive hyperemia
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Tolazoline
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 52
Study: 30272528

Group type: EXPERIMENTAL
Intervention: 150 μg/day iodine
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 300 μg/day iodine
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: COMPARATOR
Intervention: Formula-fed group
Number of subjects: 240
Study: 26761728

Group type: EXPERIMENTAL
Intervention: HRRP policy exposure (hospitals facing greater financial risk)
Number of subjects: 0
Study: 25733331

Group type: EXPERIMENTAL
Intervention: Large doses of ambroxol hydrochloride
Number of subjects: 56

Group type: COMPARATOR
Intervention: Normal doses of ambroxol hydrochloride
Number of subjects: 56
Study: 23941563

Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy of the Participatory Approach (PA) including a working group, supervisor training, and supervisor coaching.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal implementation strategy of the Participatory Approach (PA) consisting of written information only.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy of the Participatory Approach (PA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Minimal implementation strategy of the Participatory Approach (PA)
Number of subjects: 0
Study: 21194660

Group type: EXPERIMENTAL
Intervention: No cost group (hard shell hip protectors without cost)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Combined group (educational session, demonstration, and free choice of hip protectors without cost)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control group (brochure about hip protectors)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 234
Study: 19235751

Group type: EXPERIMENTAL
Intervention: Contact endoscopy in the non-RT group
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Contact endoscopy in the post-RT group
Number of subjects: 157
Study: 17032185

Group type: EXPERIMENTAL
Intervention: Propofol alone titrated to deep sedation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Combination therapy (fentanyl plus propofol, midazolam plus propofol, fentanyl plus midazolam plus propofol)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Fentanyl and propofol
Number of subjects: 200
Study: 12750084

Group type: EXPERIMENTAL
Intervention: Viscocanalostomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 50
Study: 10669283

Group type: EXPERIMENTAL
Intervention: Oral ketamine 6.0 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rectal diazepam 0.5 mg/kg and diclofenac 12.5 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 5 microg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group KS (ketamine)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Group DS (diazepam/diclofenac)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Group KG (ketamine with glycopyrrolate)
Number of subjects: 100
Study: 9602199

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Relaxation therapy
Number of subjects: 32
Study: 7845777

Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 33

Group type: COMPARATOR
Intervention: DDD pacing
Number of subjects: 33

Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 33
Study: 3177831

Group type: EXPERIMENTAL
Intervention: Midazolam (0.15 mg/kg) combined with Piritramid (0.1 mg/kg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Thalamonal (0.04 ml/kg)
Number of subjects: 70
Study: 30676232

Group type: EXPERIMENTAL
Intervention: Total body resistance exercise program for 8 weeks, 3 sessions per week.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual care and daily activities (Control group).
Number of subjects: 34
Study: 30897129

Group type: EXPERIMENTAL
Intervention: Nutrition education and diet plan
Number of subjects: 115

Group type: COMPARATOR
Intervention: General education only (Control)
Number of subjects: 115
Study: 29031658

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.33% topical gel
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard-of-care MMS
Number of subjects: 24
Study: 26337307

Group type: EXPERIMENTAL
Intervention: DIABENIL* (generic product)
Number of subjects: 24

Group type: COMPARATOR
Intervention: DAONIL* (reference product)
Number of subjects: 24
Study: 23804960

Group type: EXPERIMENTAL
Intervention: Reappraisal intervention in Year 2
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control condition (no intervention in Year 2)
Number of subjects: 120
Study: 21166575

Group type: EXPERIMENTAL
Intervention: Intensive therapy targeting normal glycosylated hemoglobin (HbA1c) levels, tight lipid control with fenofibrate and statin, aggressive blood pressure treatment with a systolic blood pressure goal of 120 mmHg
Number of subjects: 10251

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 10251